These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 17243162)

  • 1. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.
    Meyer S; Fergusson WD; Whetton AD; Moreira-Leite F; Pepper SD; Miller C; Saunders EK; White DJ; Will AM; Eden T; Ikeda H; Ullmann R; Tuerkmen S; Gerlach A; Klopocki E; Tönnies H
    Genes Chromosomes Cancer; 2007 Apr; 46(4):359-72. PubMed ID: 17243162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1.
    Storlazzi CT; Anelli L; Albano F; Zagaria A; Ventura M; Rocchi M; Panagopoulos I; Pannunzio A; Ottaviani E; Liso V; Specchia G
    Ann Hematol; 2004 Feb; 83(2):78-83. PubMed ID: 14551738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
    Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Lugthart S; Hollink IH; Arentsen-Peters ST; van Wering ER; de Graaf SS; Reinhardt D; Creutzig U; Kaspers GJ; de Bont ES; Stary J; Trka J; Zimmermann M; Beverloo HB; Pieters R; Delwel R; Zwaan CM; van den Heuvel-Eibrink MM
    Leukemia; 2010 May; 24(5):942-9. PubMed ID: 20357826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies.
    Bobadilla D; Enriquez EL; Alvarez G; Gaytan P; Smith D; Slovak ML
    Br J Haematol; 2007 Mar; 136(6):806-13. PubMed ID: 17341266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
    Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
    Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute panmyelosis with myelofibrosis with EVI1 amplification.
    Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
    Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements.
    Madrigal I; Carrió A; Gómez C; Rozman M; Esteve J; Nomdedeu B; Campo E; Costa D
    Cancer Genet Cytogenet; 2006 Oct; 170(2):115-20. PubMed ID: 17011981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-linker-sensitive myeloid leukemia cell line from a 2-year-old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations.
    Meyer S; Fergusson WD; Oostra AB; Medhurst AL; Waisfisz Q; de Winter JP; Chen F; Carr TF; Clayton-Smith J; Clancy T; Green M; Barber L; Eden OB; Will AM; Joenje H; Taylor GM
    Genes Chromosomes Cancer; 2005 Apr; 42(4):404-15. PubMed ID: 15645491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22.
    De Weer A; Speleman F; Cauwelier B; Van Roy N; Yigit N; Verhasselt B; De Moerloose B; Benoit Y; Noens L; Selleslag D; Lippert E; Struski S; Bastard C; De Paepe A; Vandenberghe P; Hagemeijer A; Dastugue N; Poppe B;
    Haematologica; 2008 Dec; 93(12):1903-7. PubMed ID: 18815193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements.
    Poppe B; Dastugue N; Vandesompele J; Cauwelier B; De Smet B; Yigit N; De Paepe A; Cervera J; Recher C; De Mas V; Hagemeijer A; Speleman F
    Genes Chromosomes Cancer; 2006 Apr; 45(4):349-56. PubMed ID: 16342172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.
    Gröschel S; Lugthart S; Schlenk RF; Valk PJ; Eiwen K; Goudswaard C; van Putten WJ; Kayser S; Verdonck LF; Lübbert M; Ossenkoppele GJ; Germing U; Schmidt-Wolf I; Schlegelberger B; Krauter J; Ganser A; Döhner H; Löwenberg B; Döhner K; Delwel R
    J Clin Oncol; 2010 Apr; 28(12):2101-7. PubMed ID: 20308656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.
    Ikeda H; Matsushita M; Waisfisz Q; Kinoshita A; Oostra AB; Nieuwint AW; De Winter JP; Hoatlin ME; Kawai Y; Sasaki MS; D'Andrea AD; Kawakami Y; Joenje H
    Cancer Res; 2003 May; 63(10):2688-94. PubMed ID: 12750298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
    Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
    Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26).
    De Braekeleer E; Douet-Guilbert N; Basinko A; Bovo C; Guéganic N; Le Bris MJ; Morel F; De Braekeleer M
    Anticancer Res; 2011 Oct; 31(10):3441-8. PubMed ID: 21965759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22).
    Bacher U; Schnittger S; Kern W; Trenn G; Weisser M; Haferlach T; Schoch C
    Cancer Genet Cytogenet; 2006 Jul; 168(2):172-4. PubMed ID: 16843110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.
    Vinatzer U; Mannhalter C; Mitterbauer M; Gruener H; Greinix H; Schmidt HH; Fonatsch C; Wieser R
    Genes Chromosomes Cancer; 2003 Jan; 36(1):80-9. PubMed ID: 12461752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.
    Baldazzi C; Luatti S; Zuffa E; Papayannidis C; Ottaviani E; Marzocchi G; Ameli G; Bardi MA; Bonaldi L; Paolini R; Gurrieri C; Rigolin GM; Cuneo A; Martinelli G; Cavo M; Testoni N
    Genes Chromosomes Cancer; 2016 Apr; 55(4):375-88. PubMed ID: 26815134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1.
    Volkert S; Schnittger S; Zenger M; Kern W; Haferlach T; Haferlach C
    Cancer Genet; 2014 Mar; 207(3):103-8. PubMed ID: 24726268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.